Rasna Therapeutics (RASP) 10-Q 20 May 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Mar. 31, 2024	May 20, 2024
Document Information Line Items
Entity Registrant Name	ACTAVIA LIFE SCIENCES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		771,811,360
Amendment Flag	false
Entity Central Index Key	0001582249
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-191083
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	39-2080103
Entity Address, Address Line One	5 Penn Plaza
Entity Address, Address Line Two	19th Floor, # 1954
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10001
City Area Code	(646)
Local Phone Number	396-4087
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash	$ 1,392	$ 74,986
Prepaid and other receivables	47,222	20,671
Total assets	48,614	95,657
Current liabilities:
Accounts payable and accrued expenses	1,503,658	1,458,216
Note payable	53,950	8,509
Convertible notes payable, net - related party	42,294	4,730
Derivative liabilities	1,862	2,036
Total Current Liabilities	2,230,363	2,051,566
Commitments and contingencies
Shareholders’ deficit
Preferred stock, $0.001 par value 20,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value; 1,500,000,000 shares authorized and 771,811,360 shares issued and outstanding at both March 31, 2024 and September 30, 2023	771,811	771,811
Additional paid-in capital	25,953,197	25,935,882
Accumulated deficit	(28,906,757)	(28,663,602)
Total shareholders’ deficit	(2,181,749)	(1,955,909)
Total liabilities and shareholders’ deficit	48,614	95,657
Related Party
Current liabilities:
Related party payables	420,881	380,339
Loan payable, related party	$ 207,718	$ 197,736

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,500,000,000	1,500,000,000
Common stock, shares issued	771,811,360	771,811,360
Common stock, shares outstanding	771,811,360	771,811,360

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative	$ 60,161	$ 93,955	$ 166,374	$ 198,811
Research and development	11,226	13,704	29,743	31,660
Common stock issued for services (see Note 6)		3,858,793		3,858,793
Total operating expenses	71,387	3,966,452	196,117	4,089,264
Loss from operations	(71,387)	(3,966,452)	(196,117)	(4,089,264)
Other income/(expense):
Accretion of debt discount	(15,837)	(164,147)	(30,697)	(180,333)
Interest expense	(8,743)	(6,489)	(17,200)	(18,191)
Gain on derivative liability	449	7,888	859	8,744
Total other expenses	(24,131)	(162,748)	(47,038)	(189,780)
Income tax provision
Net loss	$ (95,518)	$ (4,129,200)	$ (243,155)	$ (4,279,044)
Basic net loss per share attributable to common shareholders (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
Basic weighted average common shares outstanding (in Shares)	771,811,360	588,518,916	771,811,360	384,249,138

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Diluted weighted average common shares outstanding	$ 0	$ 0	$ 0	$ 0
Diluted weighted average common shares outstanding (in Shares)	771,811,360	588,518,916	771,811,360	384,249,138

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders’ Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2022	$ 179,979	$ 22,352,491	$ (24,221,067)	$ (1,688,597)
Balance (in Shares) at Sep. 30, 2022	179,979,361
Beneficial conversion feature related to convertible notes		28,800		28,800
Issuance of stock for the conversion of promissory notes	$ 209,773			209,773
Issuance of stock for the conversion of promissory notes (in Shares)	209,773,333
Common stock issued for services	$ 382,059	3,476,734		3,858,793
Common stock issued for services (in Shares)	382,058,666
Net loss			(4,279,044)	(4,279,044)
Balance at Mar. 31, 2023	$ 771,811	25,858,025	(28,500,111)	(1,870,275)
Balance (in Shares) at Mar. 31, 2023	771,811,360
Balance at Sep. 30, 2022	$ 179,979	22,352,491	(24,221,067)	(1,688,597)
Balance (in Shares) at Sep. 30, 2022	179,979,361
Balance at Sep. 30, 2023	$ 771,811	25,935,882	(28,663,602)	(1,955,909)
Balance (in Shares) at Sep. 30, 2023	771,811,360
Balance at Dec. 31, 2022	$ 179,979	22,381,291	(24,370,911)	(1,809,641)
Balance (in Shares) at Dec. 31, 2022	179,979,361
Issuance of stock for the conversion of promissory notes	$ 209,773			209,773
Issuance of stock for the conversion of promissory notes (in Shares)	209,773,333
Common stock issued for services	$ 382,059	3,476,734		3,858,793
Common stock issued for services (in Shares)	382,058,666
Net loss			(4,129,200)	(4,129,200)
Balance at Mar. 31, 2023	$ 771,811	25,858,025	(28,500,111)	(1,870,275)
Balance (in Shares) at Mar. 31, 2023	771,811,360
Balance at Sep. 30, 2023	$ 771,811	25,935,882	(28,663,602)	(1,955,909)
Balance (in Shares) at Sep. 30, 2023	771,811,360
Beneficial conversion feature related to convertible notes		17,315		17,315
Net loss			(243,155)	(243,155)
Balance at Mar. 31, 2024	$ 771,811	25,953,197	(28,906,757)	(2,181,749)
Balance (in Shares) at Mar. 31, 2024	771,811,360
Balance at Dec. 31, 2023	$ 771,811	25,935,882	(28,811,239)	(2,103,546)
Balance (in Shares) at Dec. 31, 2023	771,811,360
Beneficial conversion feature related to convertible notes		17,315		17,315
Net loss			(95,518)	(95,518)
Balance at Mar. 31, 2024	$ 771,811	$ 25,953,197	$ (28,906,757)	$ (2,181,749)
Balance (in Shares) at Mar. 31, 2024	771,811,360

Condensed Consolidated Statem_4

Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (243,155)	$ (4,279,044)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	16,849	18,191
Accretion of debt discount	30,697	180,333
Derivative liability	(859)	(8,744)
Common stock issued for services		3,858,793
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	45,442	113,932
Related party payable	40,542	41,596
Prepayments and other receivables	27,399	49,786
Net cash used in operating activities	(83,085)	(25,157)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable	18,000	30,000
Payments on note payable	(8,509)	(41,985)
Net cash provided by (used in) financing activities	9,491	(11,985)
Net change in cash	(73,594)	(37,142)
Cash, beginning of period	74,986	39,363
Cash, end of period	1,392	2,221
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Derivative liabilities in connection with issuance of convertible notes.	685	1,200
Beneficial conversion feature related to issuance a of convertible notes	17,315	28,800
Issuance of common stock for conversions of promissory notes		209,773
Issuance of note payable relating to renewal of insurance policy	$ 53,950	$ 53,950

General Information

General Information	6 Months Ended
	Mar. 31, 2024
General Information [Abstract]
GENERAL INFORMATION	1. GENERAL INFORMATION Actavia Life Sciences, Inc. (f/k/a Rasna Therapeutics, Inc. the “Company”) is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular target LSD1, which is implicated in the disease progression of leukemia and lymphoma. These unaudited condensed consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates. Risks and Uncertainties Management continues to evaluate the impact of inflation and the economic environment on the Company, and has concluded that while it is reasonably possible that inflation could have a negative effect on the Company’s financial position, results of its operations and/or ability to secure additional cash resources, there is no current impact as cash resources are currently secured by existing shareholders. The financial statements do not include any adjustments that might result from this uncertainty.

Accounting Policies

Accounting Policies	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
ACCOUNTING POLICIES	2. ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these unaudited condensed consolidated financial statements are set out below. These policies have been applied consistently to all the periods presented unless otherwise stated. There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K for the Fiscal year ended September 30, 2023. Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the “SEC”) and United States generally accepted accounting principles (“US GAAP”) for interim reporting. The principles for condensed interim financial information do not require the inclusion of all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2023 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on January 5, 2024. The accompanying unaudited condensed consolidated financial statements have not been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management, such financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The results of the operations for the three and six months ended March 31, 2024 may not be indicative of the results that may be expected for the year ending September 30, 2024. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations. Net loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using various methods such as the treasury stock, modified treasury stock, and if converted methods in the determination of dilutive shares outstanding during each reporting period. The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. March 31, March 31, Stock options 452,500 938,675 Warrants 1,926,501 1,926,501 Convertible notes and associated fees 105,720,000 - Total shares issuable upon exercise or conversion 108,099,001 2,865,176 Recent Accounting Pronouncements The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Mar. 31, 2024
Liquidity and Going Concern [Abstract]
LIQUIDITY AND GOING CONCERN	3. LIQUIDITY AND GOING CONCERN The Company has no present revenue and has experienced net losses and significant cash outflows from cash used in operating activities since inception. The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company’s cost structure. The Company has experienced net losses and significant cash outflows from cash used in operating activities and as of March 31, 2024, had an accumulated deficit of $28,906,757, a net loss for the six months ended March 31, 2024 of $243,155 and net cash used in operating activities of $83,085. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months and will require significant additional cash resources to launch new development phases of existing products in its pipeline. In the event that the Company is unable to secure the additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern one year from the date of this filing. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure.

Convertible Notes

Convertible Notes	6 Months Ended
	Mar. 31, 2024
Convertible Notes [Abstract]
CONVERTIBLE NOTES	4. CONVERTIBLE NOTES The table below summarizes outstanding convertible notes as of March 31, 2024 and March 31, 2023: Balance of convertible notes payable- related party, net as of September 30, 2023 $ 4,730 Issuance of debt 18,000 Accrued Interest 6,867 Accretion of debt discount 30,697 Beneficial conversion feature related to issuance of convertible notes (17,315 ) Derivative liabilities in connection with issuance of convertible notes (685 ) Balance of related party notes payable, net as of March 31, 2024 $ 42,294 Balance of convertible notes payable- related party, net as of September 30, 2022 $ 20,900 Issuance of debt 30,000 Accrued Interest 8,540 Accretion of debt discount 180,333 Beneficial conversion feature related to issuance of convertible notes (28,800 ) Derivative liabilities in connection with issuance of convertible notes (1,200 ) Conversion of convertible notes (209,773 ) Balance of related party notes payable, net as of March 31, 2023 $ - On February 15, 2024, the Company entered into the seventeenth 16% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $18,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.001 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity. Embedded Derivative Liability Under the promissory note agreement, the interest rate will reset upon the event of a default and an additional penalty of 2% will be accrued. The Company analyzed the conversion features of the note agreement for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined the interest rate resets met the definition of a derivative. It also noted that the Contingent Interest Rate feature required bifurcation from the host note contract and was to be accounted for at fair value. In accordance with ASC 815-15, the Company bifurcated the Contingent Interest Rate feature of the note and recorded a derivative liability. The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. During the three and six months ended March 31, 2024, the Company recognized an additional $685 due to the issuance of the convertible notes. Beneficial Conversion Feature The conversion features for all notes issued are in the money as of the issuance date and accordingly a beneficial conversion feature was recorded upon issuance. As the intrinsic value of the beneficial conversion feature exceeds the face value, the recorded beneficial conversion feature was limited to the gross proceeds less any debt discounts.

Note Payable

Note Payable	6 Months Ended
	Mar. 31, 2024
Note Payable [Abstract]
NOTE PAYABLE	5. NOTE PAYABLE On March 31, 2024, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $53,950. Under the terms of the agreement, the Company was required to make a down payment of $13,500, with the remaining balance financed over the remaining term at an annual percentage rate of 7.99%, resulting in a finance charge of $1,359. Beginning in March 2024, the Company is making 9 monthly payments of $4,645, with the last payment made in November 2024. The interest expense for this note payable for the three months ended March 31, 2024 was $270. The company made the down payment and first instalment in April 2024. On March 31, 2023, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $53,950. Under the terms of the agreement, the Company made a down payment of $13,500, with the remaining balance financed over the remaining term at an annual percentage rate of 6.99%, resulting in a finance charge of $1,187. Beginning in March 2023, the Company made 9 monthly payments of $4,626, with the last payment made in November 2023. The interest expense for this note payable for the three ended March 31, 2023 was $236.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS The following is a summary of the related party transactions for the periods presented. During the normal course of its business, the Company enters into various transactions with entities that are both businesses and individuals. The following is a summary of the related party transactions for the periods presented. Gabriele Cerrone/Panetta Partners Panetta Partners Limited, a shareholder of Actavia, is a company in which Gabriele Cerrone is a major shareholder and also serves as a director. As of March 31, 2024, and September 30, 2023, the balance due to Gabriele Cerrone was $175,000 for past consultancy services, which is presented as a component of related party payables. In September 2023, the Company entered into an additional promissory note with Panetta Partners Ltd for $80,000. The note carries an interest rate of 16% with a conversion price of $0.001 and is due for repayment by December 31, 2024. As of March 31, 2024, $87,360 was due with respect to this note issued. In February 2024, the Company entered into an additional promissory note with Panetta Partners Ltd for $18,000. The note carries an interest rate of 16% with a conversion price of $0.001 and is due for repayment by December 31, 2024. As of March 31, 2024, $18,360 was due with respect to this note issued. Apart from the Convertible Promissory Notes, there is no interest charged on the balances with related parties. There are no defined repayment terms, and such amounts can be called for payment at any time. Tiziana Life Sciences (“Tiziana”) The Company is party to a Shared Services Agreement with Tiziana, whereby the Company is charged for shared services and rent. Keeren Shah, the Company’s Chief Financial Officer, is also Chief Financial Officer of Tiziana, and the Company’s directors, Willy Simon and John Brancaccio are also non-executive directors of Tiziana. As of March 31, 2024, and September 30, 2023, $245,881 and $205,340, respectively, was due to Tiziana under services charged under the shared services agreement and other expenses paid by Tiziana on behalf of the Company. This is recorded as a related party payable in the accompanying condensed consolidated balance sheets. In March 2020, Tiziana extended a loan facility to Rasna of $65,000. The loan is repayable within 18 months and is incurring an interest charge of 8% per annum. In April 2020, the loan facility was extended by a further $7,000, so the loan facility totals $72,000. As of March 31, 2024, the amount due to Tiziana under this loan facility was $95,040. The amount due to Tiziana under this agreement as of September 30, 2023 was $93,600. In July 2022, Tiziana extended another loan facility to Rasna of $85,000. The loan is repayable within 18 months and is incurring an interest charge of 16% per annum. As of March 31, 2024, the amount due to Tiziana under this loan facility was $112,678. As of September 30, 2023, the amount due to Tiziana under this loan facility was $105,576. Apart from the Convertible Promissory Notes, there is no interest charged on the balances with related parties. There are no defined repayment terms, and such amounts can be called for payment at any time.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	7. SUBSEQUENT EVENT In May 2024, the Company entered into a promissory note with Panetta Partners Ltd for $60,000. The note carries an interest rate of 16% with a conversion price of $0.001 and is due for repayment by December 31, 2025.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of preparation	Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the “SEC”) and United States generally accepted accounting principles (“US GAAP”) for interim reporting. The principles for condensed interim financial information do not require the inclusion of all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2023 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on January 5, 2024. The accompanying unaudited condensed consolidated financial statements have not been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management, such financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The results of the operations for the three and six months ended March 31, 2024 may not be indicative of the results that may be expected for the year ending September 30, 2024.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.
Net loss per Share	Net loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using various methods such as the treasury stock, modified treasury stock, and if converted methods in the determination of dilutive shares outstanding during each reporting period. The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. March 31, March 31, Stock options 452,500 938,675 Warrants 1,926,501 1,926,501 Convertible notes and associated fees 105,720,000 - Total shares issuable upon exercise or conversion 108,099,001 2,865,176
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

Accounting Policies (Tables)

Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Diluted Weighted Average Shares Outstanding	The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. March 31, March 31, Stock options 452,500 938,675 Warrants 1,926,501 1,926,501 Convertible notes and associated fees 105,720,000 - Total shares issuable upon exercise or conversion 108,099,001 2,865,176

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended
	Mar. 31, 2024
Convertible Notes [Abstract]
Schedule of Outstanding Convertible Notes	The table below summarizes outstanding convertible notes as of March 31, 2024 and March 31, 2023: Balance of convertible notes payable- related party, net as of September 30, 2023 $ 4,730 Issuance of debt 18,000 Accrued Interest 6,867 Accretion of debt discount 30,697 Beneficial conversion feature related to issuance of convertible notes (17,315 ) Derivative liabilities in connection with issuance of convertible notes (685 ) Balance of related party notes payable, net as of March 31, 2024 $ 42,294 Balance of convertible notes payable- related party, net as of September 30, 2022 $ 20,900 Issuance of debt 30,000 Accrued Interest 8,540 Accretion of debt discount 180,333 Beneficial conversion feature related to issuance of convertible notes (28,800 ) Derivative liabilities in connection with issuance of convertible notes (1,200 ) Conversion of convertible notes (209,773 ) Balance of related party notes payable, net as of March 31, 2023 $ -

Accounting Policies (Details) -

Accounting Policies (Details) - Schedule of Diluted Weighted Average Shares Outstanding - shares	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Diluted Weighted Average Shares Outstanding [Line Items]
Total shares issuable upon exercise or conversion	108,099,001	2,865,176
Stock Options [Member]
Schedule of Diluted Weighted Average Shares Outstanding [Line Items]
Total shares issuable upon exercise or conversion	452,500	938,675
Warrants [Member]
Schedule of Diluted Weighted Average Shares Outstanding [Line Items]
Total shares issuable upon exercise or conversion	1,926,501	1,926,501
Convertible notes & associated fees [Member]
Schedule of Diluted Weighted Average Shares Outstanding [Line Items]
Total shares issuable upon exercise or conversion	105,720,000

Liquidity and Going Concern (De

Liquidity and Going Concern (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Liquidity and Going Concern [Line Items]
Accumulated deficit	$ (28,906,757)		$ (28,906,757)		$ (28,663,602)
Net loss	$ (95,518)	$ (4,129,200)	(243,155)	$ (4,279,044)
Net cash used in operating activities			$ (83,085)	$ (25,157)

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)			3 Months Ended			6 Months Ended
	Feb. 15, 2024	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Convertible Notes [Line Items]
Cash	$ 18,000
Conversion price per share (in Dollars per share)	$ 0.001
Equity financing cost	$ 1,000,000
Interest rate			2%			2%
Recognized issuance cost			$ 685			$ 685
Gain on derivative liability			$ 449		$ 7,888	859	$ 8,744
Beneficial conversion feature		$ 28,800		$ 17,315		$ 17,315	28,800
Convertible Promissory Note [Member]
Convertible Notes [Line Items]
Debt instrument percentage	16%
Embedded Derivative Liability [Member]
Convertible Notes [Line Items]
Additional derivative liability					$ 1,200		$ 1,200

Convertible Notes (Details) - S

Convertible Notes (Details) - Schedule of Outstanding Convertible Notes - Related Party Notes Payable [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Summarizes Outstanding Convertible Notes [Line Items]
Beginning balance	$ 4,730	$ 20,900
Issuance of debt	18,000	30,000
Accrued Interest	6,867	8,540
Accretion of debt discount	30,697	180,333
Beneficial conversion feature related to issuance of convertible notes	(17,315)	(28,800)
Derivative liabilities in connection with issuance of convertible notes	(685)	(1,200)
Conversion of convertible notes		(209,773)
Ending balance	$ 42,294

Note Payable (Details)

Note Payable (Details) - USD ($)			3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Note Payable [Abstract]
Insurance agreement	$ 53,950	$ 53,950	$ 53,950	$ 53,950
Down payment	$ 13,500	$ 13,500	13,500	13,500
Annual percentage	7.99%	6.99%
Finance charge	$ 1,359	$ 1,187	1,359	1,187
Monthly payments	$ 4,645	$ 4,626
Interest expense			$ 270	$ 236

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2025	Dec. 31, 2024	Feb. 29, 2024	Jul. 31, 2022	Apr. 30, 2020	Mar. 31, 2020
Related Party Transactions [Line Items]
Balance due		$ 175,000		$ 175,000
Due on issued notes		87,360
Service charges	$ 3,858,793		$ 3,858,793
Loan facility amount		95,040						$ 85,000	$ 7,000	$ 65,000
Loan facility totals									$ 72,000
Due amount				93,600
Tiziana Life Sciences Plc [Member]
Related Party Transactions [Line Items]
Interest rate, percentage								16%		8%
Service charges		245,881		205,340
Maximum [Member] | Tiziana Life Sciences Plc [Member]
Related Party Transactions [Line Items]
Loan facility amount				105,576
Roberto Pellicciari and TES Pharma [Member] | Minimum [Member]
Related Party Transactions [Line Items]
Due amount		112,678
Panetta Partners Ltd [Member]
Related Party Transactions [Line Items]
Promissory note				$ 80,000			$ 18,000
Due on issued notes		$ 18,360
Forecast [Member]
Related Party Transactions [Line Items]
Conversion price (in Dollars per share)						$ 0.001
Forecast [Member] | Gabriele Cerrone/Panetta Partners [Member]
Related Party Transactions [Line Items]
Interest rate, percentage						16%
Conversion price (in Dollars per share)						$ 0.001
Forecast [Member] | Panetta Partners Ltd [Member]
Related Party Transactions [Line Items]
Interest rate, percentage					16%	16%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	May 31, 2024
Subsequent Event [Member]
Subsequent Event [Line Items]
Promissory note			$ 60,000
Forecast [Member] | Panetta Partners Ltd [Member]
Subsequent Event [Line Items]
Interest rate	16%	16%
Conversion price	$ 0.001